Literature DB >> 11253616

Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.

D M Reith1, W D Hooper, J Parke, B Charles.   

Abstract

Carbamazepine (CBZ) clearance decreases from childhood to adulthood and the factors determining this change could include age, size, autoinduction, or maturational changes. This study aims to describe the population pharmacokinetics of CBZ in children and young adults and test the hypothesis that CBZ clearance correlates with weight, surface area, and age. CBZ therapeutic drug monitoring data (sparse data) were collected from child and adult epileptics, and rich data were obtained from a bioequivalence study of CBZ in young adults. Population pharmaco-kinetic analysis was performed using NONMEM V. Forward stepwise, multiple regression was performed on the covariates. Bootstrap validation was performed. A total of 946 observations from 91 subjects, ages 0.7-37 years, were collected and analyzed. A one-compartment, first-order absorption and elimination model, with exponential interindividual error and additive residual error models was developed. The population model was: Clearance (Lhr-1) = ((2.24 x Surface area (m2)) + (0.047 x Dose (mg.kg-1)); Volume of distribution (L) = 0.37 x weight (kg); Absorption rate constant = 0.013 (hr-1). CBZ clearance increased with surface area and dose.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253616     DOI: 10.1023/a:1011569703060

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  20 in total

1.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

2.  A size standard for pharmacokinetics.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

3.  On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.

Authors:  H Sun; E I Ette; T M Ludden
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

4.  The influence of assay variability on pharmacokinetic parameter estimation.

Authors:  D A Graves; C S Locke; K T Muir; R P Miller
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

5.  Calculation of drug dosage and body surface area of children.

Authors:  J A Lack; M E Stuart-Taylor
Journal:  Br J Anaesth       Date:  1997-05       Impact factor: 9.166

6.  Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data.

Authors:  E Yukawa; T Aoyama
Journal:  J Clin Pharmacol       Date:  1996-08       Impact factor: 3.126

7.  Simplified calculation of body-surface area.

Authors:  R D Mosteller
Journal:  N Engl J Med       Date:  1987-10-22       Impact factor: 91.245

Review 8.  Clinical pharmacokinetics of anticonvulsants.

Authors:  E F Hvidberg; M Dam
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  A model for the determination of carbamazepine clearance in children on mono- and polytherapy.

Authors:  A L Gray; J H Botha; R Miller
Journal:  Eur J Clin Pharmacol       Date:  1998-06       Impact factor: 2.953

10.  [Estimation of liver volume as a function of the individual's morphology].

Authors:  J Carles; J el Kohen; D Midy; J Saric; J Videau
Journal:  Bull Assoc Anat (Nancy)       Date:  1993-09
View more
  11 in total

1.  Population pharmacokinetics of carbamazepine in elderly patients.

Authors:  Baralee Punyawudho; Eugene R Ramsay; Richard C Brundage; Flavia M Macias; Joseph F Collins; Angela K Birnbaum
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

2.  Statistical issues in a modeling approach to assessing bioequivalence or PK similarity with presence of sparsely sampled subjects.

Authors:  Chuanpu Hu; Katy H P Moore; Yong H Kim; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-08       Impact factor: 2.745

Review 3.  The global burden of non-conflict related firearm mortality.

Authors:  T S Richmond; R Cheney; C W Schwab
Journal:  Inj Prev       Date:  2005-12       Impact factor: 2.399

4.  Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses.

Authors:  Jae Eun Ahn; Angela K Birnbaum; Richard C Brundage
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

5.  Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine.

Authors:  Min Zhu; Sanjeev Kaul; Partha Nandy; Dennis M Grasela; Marc Pfister
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

6.  Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.

Authors:  Ghada F Ahmed; Richard C Brundage; Susan E Marino; James C Cloyd; Ilo E Leppik; Page B Pennell; R Eugene Ramsay; Angela K Birnbaum
Journal:  J Clin Pharmacol       Date:  2013-02-13       Impact factor: 3.126

7.  A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures.

Authors:  Joanie K Tulloch; Roxane R Carr; Mary H H Ensom
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

8.  Investigating Oral Absorption of Carbamazepine in Pediatric Populations.

Authors:  Philip Kohlmann; Cordula Stillhart; Martin Kuentz; Neil Parrott
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

9.  CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.

Authors:  Natasa Djordjevic; Dragana Dragas Milovanovic; Marija Radovanovic; Ivan Radosavljevic; Slobodan Obradovic; Mihajlo Jakovljevic; Dragan Milovanovic; Jasmina R Milovanovic; Slobodan Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-14       Impact factor: 2.953

10.  Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.

Authors:  Vincent L M Yip; Henry Pertinez; Xiaoli Meng; James L Maggs; Daniel F Carr; B Kevin Park; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2020-12-14       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.